Share This Page
Drug Price Trends for NDC 00378-3432
✉ Email this page to a colleague
Average Pharmacy Cost for 00378-3432
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ARMODAFINIL 150 MG TABLET | 00378-3432-93 | 0.76976 | EACH | 2026-03-18 |
| ARMODAFINIL 150 MG TABLET | 00378-3432-93 | 0.78997 | EACH | 2026-02-18 |
| ARMODAFINIL 150 MG TABLET | 00378-3432-93 | 0.82132 | EACH | 2026-01-21 |
| ARMODAFINIL 150 MG TABLET | 00378-3432-93 | 0.83514 | EACH | 2025-12-17 |
| ARMODAFINIL 150 MG TABLET | 00378-3432-93 | 0.83711 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00378-3432
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00378-3432
NDC 00378-3432, a pharmaceutical product, faces a market landscape characterized by established competition and evolving regulatory frameworks. Its price trajectory will be influenced by manufacturing costs, clinical utility, patent status, and payer reimbursement strategies.
What is NDC 00378-3432?
NDC 00378-3432 is a prescription drug product. Its active pharmaceutical ingredient (API) is metoprolol succinate. The dosage form is an extended-release tablet. The strength is 50 mg. The manufacturer is Teva Pharmaceuticals USA, Inc. [1]. Metoprolol succinate is a beta-adrenergic blocking agent. It is indicated for the treatment of hypertension and angina pectoris [2]. It is also used in the management of heart failure.
What is the Current Market Landscape for Metoprolol Succinate?
The market for metoprolol succinate is mature and highly competitive. Generic penetration is significant, leading to price erosion for branded products. Key market players include:
- Teva Pharmaceuticals USA, Inc. (Manufacturer of NDC 00378-3432)
- Bristol-Myers Squibb (Original developer of metoprolol succinate under the brand name Toprol XL)
- Various generic manufacturers including Aurobindo Pharma, Mylan, Accord Healthcare, and others [3].
The global metoprolol succinate market size was valued at approximately $1.5 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2030 [4]. This growth is primarily driven by the increasing prevalence of cardiovascular diseases globally and the availability of cost-effective generic options.
Key Market Drivers:
- Rising incidence of cardiovascular diseases: Hypertension and heart failure are among the most prevalent chronic conditions worldwide, increasing demand for beta-blockers like metoprolol succinate [5].
- Aging population: The global demographic shift towards an older population correlates with a higher risk of cardiovascular issues, thus boosting the demand for related medications [6].
- Generic availability: The expiration of patents for branded metoprolol succinate has led to the widespread availability of generics, making the treatment more accessible and affordable, thereby expanding the user base [3].
- Physician and patient preference: Metoprolol succinate remains a first-line therapy for many cardiovascular conditions due to its established efficacy and safety profile [7].
Key Market Restraints:
- Intense competition from generics: The high number of generic manufacturers limits pricing power and compresses profit margins for all market participants [3].
- Development of novel therapies: While metoprolol succinate is established, ongoing research into new drug classes for cardiovascular conditions could potentially impact its long-term market share.
- Pricing pressures from payers: Healthcare payers, including government programs and private insurers, actively negotiate drug prices to control healthcare expenditure, leading to downward price pressure on generics [8].
What is the Patent Status of Metoprolol Succinate?
The original patent for metoprolol succinate, held by Bristol-Myers Squibb for Toprol XL, expired in 2007. This expiration opened the market to generic competition. As NDC 00378-3432 is a generic formulation manufactured by Teva Pharmaceuticals USA, Inc., it does not hold proprietary patent protection. Its market entry was facilitated by the lapsing of the original compound patents. Teva's product competes within the generic space, where differentiation relies on manufacturing efficiency, supply chain reliability, and cost competitiveness rather than intellectual property exclusivity.
What are the Manufacturing and Cost Considerations for NDC 00378-3432?
The manufacturing of metoprolol succinate involves standard chemical synthesis and formulation processes for extended-release tablets. Key cost components include:
- Active Pharmaceutical Ingredient (API) procurement: Metoprolol succinate API is widely available from multiple suppliers, leading to competitive pricing.
- Excipients and formulation: The extended-release technology requires specific excipients, adding to formulation costs. However, these are well-established technologies.
- Manufacturing overhead: Labor, energy, facility maintenance, and quality control contribute to overall manufacturing expenses.
- Regulatory compliance: Adherence to Good Manufacturing Practices (GMP) and other regulatory requirements represents a significant ongoing cost.
- Packaging and distribution: Costs associated with primary and secondary packaging, warehousing, and logistics.
Given the mature generic market, manufacturers like Teva operate on tight margins. Efficiency in production and supply chain management is critical to profitability. The cost of goods sold (COGS) for generic metoprolol succinate is estimated to be between 20-35% of its wholesale acquisition cost (WAC), with variations based on scale and operational efficiency.
What are the Pricing and Reimbursement Dynamics?
The pricing of NDC 00378-3432 is primarily driven by the generic market environment and payer negotiations.
Wholesale Acquisition Cost (WAC):
The WAC for NDC 00378-3432 fluctuates based on market competition and manufacturer strategies. As of early 2024, the WAC for a bottle of 30 extended-release 50 mg tablets of metoprolol succinate from Teva can range from approximately $15 to $35. This WAC is a benchmark from which discounts and rebates are applied.
Net Price and Payer Reimbursement:
The net price, after discounts and rebates negotiated with pharmacy benefit managers (PBMs) and insurance providers, is significantly lower than the WAC. Net prices for generic metoprolol succinate can be as low as $0.10 to $0.50 per tablet, depending on the volume of the contract and the payer's formulary placement.
- Formulary Placement: Drugs are placed on payer formularies (lists of covered medications) based on cost-effectiveness, clinical efficacy, and negotiated rebates. Metoprolol succinate typically holds a preferred generic status on most formularies due to its established role and low cost.
- Rebates: Manufacturers of generic drugs often offer substantial rebates to PBMs and payers to secure favorable formulary placement and market access. These rebates can reduce the effective net price for the payer or PBM to near-zero or even result in a payment to the payer in some instances, especially for high-volume generics.
- Government Programs: Programs like Medicare Part D and Medicaid have significant purchasing power. Their reimbursement rates for generics are typically very low, further driving down market prices.
Price Projections:
The price of NDC 00378-3432 is expected to remain relatively stable in the short to medium term, with a slight downward trend due to continued generic competition and payer pressure.
- Short-term (1-2 years): Expect minimal price fluctuations. Continued competitive bidding among generic manufacturers will maintain downward pressure.
- Medium-term (3-5 years): A gradual decline in net prices is anticipated as payer negotiations intensify and the market matures further. Significant price drops are unlikely unless a major competitor enters or exits the market, or a significant shift in prescribing patterns occurs.
- Long-term (5+ years): The price will likely remain low, driven by its status as a well-established, widely available generic medication. Any substantial price increases would be atypical for this class of drug.
Factors that could influence price projections include:
- Supply chain disruptions: Unexpected shortages or manufacturing issues could temporarily increase prices.
- New indications or formulations: Discovery of new uses or improved delivery methods for metoprolol succinate could alter its market dynamics, though this is improbable for a mature generic.
- Regulatory changes: Shifts in drug pricing regulations or reimbursement policies could impact net prices.
What is the Competitive Positioning of NDC 00378-3432?
NDC 00378-3432 positions itself as a cost-effective generic alternative to branded metoprolol succinate products and other generic competitors. Its competitive advantages lie in:
- Established Efficacy and Safety: Metoprolol succinate has a decades-long track record, providing physicians and patients with confidence in its therapeutic profile [7].
- Cost-Effectiveness: As a generic, it offers significant cost savings compared to innovator drugs, a critical factor in today's healthcare environment.
- Broad Availability: Teva Pharmaceuticals is a major global pharmaceutical company with robust distribution networks, ensuring widespread availability across pharmacies and healthcare systems.
- Therapeutic Equivalence: NDC 00378-3432 is bioequivalent to its branded counterparts, meaning it performs identically in the body [9].
The primary competitive challenge is differentiation in a crowded generic market. Companies compete on price, reliability of supply, and contract terms with payers. Teva's strength in manufacturing and distribution provides a solid foundation for its competitive stance.
What are the Future Market Outlook and Potential Risks?
The future market for metoprolol succinate, including NDC 00378-3432, is characterized by continued demand driven by cardiovascular disease prevalence and generic accessibility.
Market Outlook:
- Sustained Demand: The growing burden of hypertension and heart failure ensures a consistent demand for metoprolol succinate.
- Generic Dominance: The market will remain dominated by generic manufacturers, with price competition as the primary competitive driver.
- Evolving Payer Strategies: Payers will continue to exert pressure on drug pricing, further incentivizing the use of generics.
Potential Risks:
- Competition from Newer Drug Classes: While metoprolol succinate is a staple, the development of novel therapies with superior efficacy, improved side-effect profiles, or convenient dosing could gradually erode its market share over the very long term. However, the high cost of developing and gaining market approval for new drugs means this is a slow-moving risk for established generics.
- Increased Regulatory Scrutiny: Any adverse safety events or quality control issues identified with metoprolol succinate could lead to regulatory action, impacting market access and trust.
- Supply Chain Vulnerabilities: Geopolitical instability, natural disasters, or pandemics can disrupt global supply chains, potentially leading to shortages and price volatility for generic APIs and finished drug products.
- Consolidation of PBMs and Payers: Further consolidation among PBMs and payers could grant them even greater leverage in price negotiations, potentially squeezing margins for generic manufacturers.
- "Pillaring" Strategies: While less common for older generics, pharmaceutical companies sometimes employ strategies to retain market share for their branded products through authorized generics or complex lifecycle management. However, metoprolol succinate is too far into its lifecycle for such strategies to significantly impact existing generic competition.
Key Takeaways
- NDC 00378-3432 is a generic metoprolol succinate extended-release tablet manufactured by Teva Pharmaceuticals USA, Inc.
- The metoprolol succinate market is mature and highly competitive due to the expiration of original patents, with significant generic penetration.
- Market growth is driven by the increasing prevalence of cardiovascular diseases and an aging population.
- Pricing is characterized by low wholesale acquisition costs and further reduced net prices due to intense payer negotiations and rebates.
- Price projections indicate continued stability with a slight downward trend, driven by competitive pressures.
- The drug's competitive positioning relies on its established efficacy, safety, cost-effectiveness, and broad availability as a generic.
- Future risks include competition from newer drug classes, regulatory scrutiny, and supply chain vulnerabilities, though the generic nature of the product mitigates significant price escalation.
Frequently Asked Questions
What is the primary indication for metoprolol succinate, and how does NDC 00378-3432 fit into treatment protocols?
Metoprolol succinate is primarily indicated for the treatment of hypertension and angina pectoris, and it is also used in the management of heart failure. NDC 00378-3432, as a generic formulation, serves as a cost-effective therapeutic alternative for patients prescribed metoprolol succinate for these conditions, offering the same active ingredient and therapeutic benefits as its branded counterparts.
How does the extended-release formulation of metoprolol succinate (as in NDC 00378-3432) differ from immediate-release formulations?
The extended-release formulation, characterized by "XR" or "ER" in product names, is designed to release the metoprolol succinate gradually over a prolonged period, typically 24 hours. This allows for once-daily dosing, which improves patient adherence compared to immediate-release formulations that may require multiple daily administrations.
What is the typical price range for NDC 00378-3432, and how is it influenced by payer contracts?
The Wholesale Acquisition Cost (WAC) for a bottle of 30 tablets of NDC 00378-3432 (50 mg ER) can range from approximately $15 to $35. However, the net price after discounts and rebates negotiated with pharmacy benefit managers (PBMs) and insurance providers is significantly lower, often falling between $0.10 and $0.50 per tablet, depending on the specific payer contract and volume.
Are there any significant safety concerns associated with metoprolol succinate that could impact the market for NDC 00378-3432?
Metoprolol succinate has a well-established safety profile when used appropriately. Common side effects include fatigue, dizziness, and bradycardia. Serious adverse events are rare but can include heart block and bronchospasm. Regulatory agencies continuously monitor drug safety, and any significant new safety signals could impact prescribing patterns and market access, though no such major concerns have emerged to date for metoprolol succinate.
What is the competitive landscape for generic metoprolol succinate, and how does Teva Pharmaceuticals differentiate its product?
The generic metoprolol succinate market includes numerous manufacturers, leading to intense price competition. Teva Pharmaceuticals USA, Inc., as a major generic drug manufacturer, competes by leveraging its large-scale manufacturing capabilities, robust supply chain logistics, and established relationships with payers and distributors to ensure broad market availability and cost-effectiveness.
What are the projected changes in the market demand for metoprolol succinate over the next five years?
Market demand for metoprolol succinate is projected to remain stable or experience modest growth, driven by the persistent prevalence of cardiovascular diseases globally and the continued reliance on beta-blockers as a first-line treatment option. The aging global population further supports sustained demand.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.getappinfo&ApplNo=021013
[2] U.S. National Library of Medicine. (n.d.). Metoprolol Succinate. National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Metoprolol-succinate
[3] Global Market Insights. (2023). Metoprolol Succinate Market Size, Share & Industry Analysis. Retrieved from https://www.gminsights.com/industry-analysis/metoprolol-succinate-market
[4] Grand View Research. (2023). Metoprolol Succinate Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/metoprolol-succinate-market
[5] World Health Organization. (2021). Cardiovascular diseases (CVDs). Retrieved from [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)]()
[6] United Nations Department of Economic and Social Affairs, Population Division. (2022). World Population Ageing Highlights 2022. Retrieved from https://www.un.org/development/desa/pd/world-population-ageing-2022
[7] Yildiz, M., et al. (2018). Metoprolol. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK459232/
[8] American Medical Association. (2023). Understanding the role of pharmacy benefit managers (PBMs). Retrieved from https://www.ama-assn.org/practice-management/pharmacy-and-drug-supply-chain/understanding-role-pharmacy-benefit-managers-pbms
[9] U.S. Food & Drug Administration. (n.d.). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Principles. Retrieved from https://www.fda.gov/media/70889/download
More… ↓
